Literature DB >> 15554759

An open trial of olanzapine in anorexia nervosa.

Nicole C Barbarich1, Claire W McConaha, Jill Gaskill, Maria La Via, Guido K Frank, Sarah Achenbach, Katherine H Plotnicov, Walter H Kaye.   

Abstract

BACKGROUND: Recent reports raise the possibility that olanzapine can assist weight gain and improve behavioral symptoms during refeeding in anorexia nervosa.
METHOD: Seventeen DSM-IV anorexia nervosa subjects hospitalized between May 1999 and October 2000 were enrolled in open-label treatment with olanzapine for up to 6 weeks. Baseline weight and symptoms were compared to patients' status at the end of treatment.
RESULTS: Olanzapine administration was associated with a significant reduction in depression, anxiety, and core eating disorder symptoms, and a significant increase in weight. A comparison with our historical data suggests that subjects in this study had a significantly greater decrease in depression.
CONCLUSION: These data lend support to the possibility that olanzapine may be useful in treating anorexia nervosa. However, a controlled trial is necessary to demonstrate that olanzapine is efficacious.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15554759     DOI: 10.4088/jcp.v65n1106

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  13 in total

1.  Olanzapine use for the adjunctive treatment of adolescents with anorexia nervosa.

Authors:  Mark L Norris; Wendy Spettigue; Annick Buchholz; Katherine A Henderson; Rebecca Gomez; Danijela Maras; Isabelle Gaboury; Andy Ni
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-04-21       Impact factor: 2.576

Review 2.  The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects.

Authors:  Guido K W Frank; Megan E Shott
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

3.  Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa.

Authors:  Vikas Duvvuri; Taya Cromley; Megan Klabunde; Kerri Boutelle; Walter H Kaye
Journal:  Int J Eat Disord       Date:  2011-02-22       Impact factor: 4.861

4.  Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice.

Authors:  Stephanie J Klenotich; Mariel P Seiglie; Matthew S McMurray; Jamie D Roitman; Daniel Le Grange; Priya Dugad; Stephanie C Dulawa
Journal:  Neuropsychopharmacology       Date:  2012-03-07       Impact factor: 7.853

Review 5.  [Serotonin reuptake inhibitors in children. Warnings on the administration, results analysis, and recommendations].

Authors:  J M Fegert; B Herpertz-Dahlmann
Journal:  Nervenarzt       Date:  2005-11       Impact factor: 1.214

6.  Tolerability and efficacy of aripiprazole in a case of psychotic anorexia nervosa comorbid with epilepsy and chronic renal failure.

Authors:  M Aragona
Journal:  Eat Weight Disord       Date:  2007-09       Impact factor: 4.652

Review 7.  Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder.

Authors:  Nicholas T Bello; Bryn L Yeomans
Journal:  Expert Opin Drug Saf       Date:  2017-10-31       Impact factor: 4.250

8.  A review of medication use for children and adolescents with eating disorders.

Authors:  Jennifer Couturier; James Lock
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2007-11

9.  Management of anorexia and bulimia nervosa: An evidence-based review.

Authors:  Kaustav Chakraborty; Debasish Basu
Journal:  Indian J Psychiatry       Date:  2010-04       Impact factor: 1.759

10.  Evaluation of the Effectiveness and Safety of Olanzapine as an Adjunctive Treatment for Anorexia Nervosa in Adolescents: An Open-Label Trial.

Authors:  Wendy Spettigue; Mark L Norris; Danijela Maras; Nicole Obeid; Stephen Feder; Megan E Harrison; Rebecca Gomez; Maeghan Cy Fu; Katherine Henderson; Annick Buchholz
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2018-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.